Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO William Richard White Sells 2,817 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO William Richard White sold 2,817 shares of Akero Therapeutics stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $30.79, for a total transaction of $86,735.43. Following the completion of the transaction, the chief financial officer now owns 38,335 shares in the company, valued at approximately $1,180,334.65. This represents a 6.85 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Akero Therapeutics Stock Performance

AKRO stock opened at $29.03 on Friday. Akero Therapeutics, Inc. has a 52 week low of $15.32 and a 52 week high of $37.00. The company’s 50-day moving average price is $30.79 and its 200 day moving average price is $27.01. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25.

Akero Therapeutics (NASDAQ:AKRO) last released its quarterly earnings data on Friday, November 8th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15). On average, equities analysts expect that Akero Therapeutics, Inc. will post -3.96 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on AKRO. HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Akero Therapeutics in a research note on Monday, November 18th. Citigroup assumed coverage on shares of Akero Therapeutics in a report on Monday, November 18th. They issued a “buy” rating and a $65.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Akero Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $46.83.

Institutional Trading of Akero Therapeutics

A number of institutional investors have recently added to or reduced their stakes in AKRO. SG Americas Securities LLC grew its position in shares of Akero Therapeutics by 191.2% in the second quarter. SG Americas Securities LLC now owns 14,517 shares of the company’s stock valued at $341,000 after purchasing an additional 9,532 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Akero Therapeutics by 32.8% in the second quarter. Bank of New York Mellon Corp now owns 251,234 shares of the company’s stock valued at $5,894,000 after purchasing an additional 61,988 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of Akero Therapeutics by 30.3% during the second quarter. Rhumbline Advisers now owns 107,338 shares of the company’s stock valued at $2,518,000 after buying an additional 24,940 shares during the period. TD Asset Management Inc lifted its stake in shares of Akero Therapeutics by 23.7% during the second quarter. TD Asset Management Inc now owns 154,592 shares of the company’s stock valued at $3,627,000 after buying an additional 29,600 shares during the period. Finally, Quest Partners LLC lifted its stake in shares of Akero Therapeutics by 22,021.1% during the second quarter. Quest Partners LLC now owns 12,609 shares of the company’s stock valued at $296,000 after buying an additional 12,552 shares during the period.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.